Msg #4006:
Msg #4024:
Msg #4011:
Msg #4012:

Dynavax Technologies Corporation

Emeryville,  CA 
United States
http://www.heplisavb.com
  • Msg #4359: Booth: 904


Welcome to our booth! Natalie Taylor (ntaylor@dynavax.com)

Dynavax Technologies is dedicated to developing innovative vaccines that modulate the immune system to prevent infectious diseases. We are the maker of the first and only 2-dose, over 1 month, hepatitis B vaccine for adults: Heplisav-B. The traditional 3-dose vaccines are associated with lower effectiveness and poor completion rates. In fact, ~75% of adults aged 19+ do not receive all 3 doses and remain under or unprotected and at-risk for acquiring hepatitis B. Heplisav-B addresses many of the limitations of the 3-dose vaccines and improves health outcomes, efficiency and can reduce overall healthcare costs.

Hepatitis B vaccines have been available for over 30 years, yet HBV infections are on the rise. Estimated new cases of hepatitis B have risen ~11% over a 5-year period and as many as 2.2 million people are infected with hepatitis B in the United States.


 Msg #4368: Products

  • Heplisav-B
    Dynavax is a biopharmaceutical company that developed an FDA approved Hepatitis-B vaccine that offers a two-dose vaccine over 1-month option to adult patients....

  • Dynavax is a commercial-stage biopharmaceutical company.  Our FDA-approved 
    Hepatitis B vaccine is the only two-dose hepatitis vaccine for adults that completes the series in 1 month.  It is the first approved hepatitis B vaccine in over 25 years and received a unanimous recommendation from the Advisory Committee on Immunization Practice.

Msg #4959: Send Email

Msg #4719: Type your information and click "Send Email" to send an email to this exhibitor. To return to the previous screen without saving, click "Reset".


Msg #4016:
Msg #4017:
Msg #4018:
Msg #4019:

Msg #4020:
Msg #4730: